Physician profile
Mir M Quadri
NPI 1235468703
$639.02
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.94 · 2020: $15.65 · 2021: $68.42 · 2022: $110 · 2023: $200 · 2024: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $166.10 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $146.67 | 2021-2024 | |
| Pfizer INC. | $94.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.44 | 2023 | Jardiance |
| Medtronic, INC. | $35.41 | 2023-2024 | Kyphon Express II Kyphopak Tray |
| Gilead Sciences, INC. | $33.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.75 | 2020-2021 | |
| Vapotherm INC | $21.07 | 2024 | Vapotherm |
| Merck Sharp & Dohme LLC | $19.93 | 2024 | Dificid, Zerbaxa, Recarbrio |
| Bioxcel Therapeutics, INC. | $18.02 | 2023 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 2022 | |
| Mylan Specialty L.P. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Quadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.